Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline in Residual Nonfunctioning Pituitary Adenoma
NCT03271918Phase 3Completed
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabergoline (2 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: Tumor shrinkage at 24 months. Started Feb 2015; status: completed.
02
Drugs
cabergoline
Beyond the preview
Go deeper on NCT03271918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271918.